Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
CONCLUSION AND RELEVANCE: Concomitant PPI use was not associated with the effectiveness of nivolumab or pembrolizumab. Certain predictors of survival outcomes related to PPI use in patients receiving immunotherapy, such as the time window and indication of PPI exposure and autoimmune disorders, should be explored in the future to better carve out the impact of PPI on the effectiveness of ICI use.PMID:34282636 | DOI:10.1177/10600280211033938
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Kangning Peng Ken Chen Benjamin A Teply Gary C Yee Paraskevi A Farazi Elizabeth R Lyden Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Head and Neck Cancer | HNSCC | Immunotherapy | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Proton Pump Inhibitors PPIs | Renal Cell Carcinoma | Skin Cancer | Squamous Cell Carcinoma | Study | Transitional Cell Carcinoma